Linked Life Data

18545239

Source:http://linkedlifedata.com/resource/pubmed/id/18545239

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-6-11
pubmed:abstractText
The use of G-CSF and GM-CSF has been shown to benefit patients undergoing autologous hematopoietic SCT (HSCT), mainly after autologous bone marrow transplantation. Their benefit in allogeneic transplant is not as pronounced and the use of growth factors in this patient group remains controversial due to conflicting reports of whether the use of growth factors increases the incidence of acute and chronic GvHD. The efficacy of EPO in HSCT patients is not well studied, but a reduction in the number of RBC transfusions has been shown in patients undergoing allogeneic transplant. Also the efficacy of thrombopoietic agents to date has not been demonstrated. One promising new approach to reduce the degree of mucositis is the use of recombinant keratinocyte growth factor.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
41 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S27-9
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Cytokines following SCT: indications and controversies.
pubmed:affiliation
BMT Unit, Hospital Sant Pau, Barcelona, Spain. ibadell@santpau.es
pubmed:publicationType
Journal Article